Revenue for the third quarter of 2024 was $45.1 million, representing an increase of 11% compared to $40.8 million in the third quarter of 2023. The increase was driven by product mix shift that ...

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 7.41% and 3.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

TMCI) on Tuesday reported a loss of $15.4 million in its third quarter. The Ponte Vedra, Florida-based company said it had a loss of 25 cents per share. The results surpassed Wall Street expectations.

With 3 analyst ratings, Treace Medical Concepts has a consensus rating of Neutral. The average one-year price target is $6.83, indicating a potential 42.89% upside.

Concepts announced the limited market release of the Nanoplasty 3D Minimally Invasive, MIS, Bunion Correction System and ...

News' Sharon Phillips' latest Cold Case investigation looks into the story of Gregory Treace who's been missing from Creek ...

BrainsWay has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) has received an average recommendation of “Hold” from the six research firms that are currently covering the company ...

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical ...

The Law Offices of Frank R. Cruz announces an investigation of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI) on behalf of investors concerning the Company's possible ...

Law Offices of Howard G. Smith announces an investigation on behalf of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI) investors concerning the Company's possible violations ...